Lilly breast cancer drug fails to improve survival in trial

(Reuters) - Eli Lilly and Co said its experimental breast cancer drug failed to improve patients' survival without their cancer worsening in a late-stage trial, dashing investors' hopes on one of the company's most talked-about drugs. Lilly shares fell 5 percent in premarket trade. The company said it does not plan to submit an approval application for the drug, ramucirumab, for treating advanced breast cancer. However, a separate trial, testing the drug as a treatment for advanced gastric cancer, met the main goal of improving patients' survival. ...



via Health News Headlines - Yahoo! News http://news.yahoo.com/lilly-drug-fails-breast-cancer-succeeds-gastric-cancer-131148496--finance.html